- Home
- KODK vs KYTX Comparison
KODK vs KYTX Comparison
Compare KODK & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KODK
- KYTX
- Stock Information
- Founded
- KODK 1880
- KYTX 2018
- Country
- KODK United States
- KYTX United States
- Employees
- KODK N/A
- KYTX N/A
- Industry
- KODK Business Services
- KYTX
- Sector
- KODK Consumer Discretionary
- KYTX
- Exchange
- KODK Nasdaq
- KYTX NYSE
- Market Cap
- KODK 393.5M
- KYTX 290.8M
- IPO Year
- KODK N/A
- KYTX 2024
- Fundamental
- Price
- KODK $4.89
- KYTX $7.34
- Analyst Decision
- KODK
- KYTX Buy
- Analyst Count
- KODK 0
- KYTX 3
- Target Price
- KODK N/A
- KYTX $26.67
- AVG Volume (30 Days)
- KODK 433.7K
- KYTX 410.5K
- Earning Date
- KODK 11-06-2024
- KYTX 08-12-2024
- Dividend Yield
- KODK N/A
- KYTX N/A
- EPS Growth
- KODK N/A
- KYTX N/A
- EPS
- KODK 0.57
- KYTX N/A
- Revenue
- KODK $1,060,000,000.00
- KYTX N/A
- Revenue This Year
- KODK N/A
- KYTX N/A
- Revenue Next Year
- KODK N/A
- KYTX N/A
- P/E Ratio
- KODK $8.62
- KYTX N/A
- Revenue Growth
- KODK N/A
- KYTX N/A
- 52 Week Low
- KODK $3.33
- KYTX $6.30
- 52 Week High
- KODK $6.18
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- KODK 40.71
- KYTX N/A
- Support Level
- KODK $4.91
- KYTX N/A
- Resistance Level
- KODK $5.45
- KYTX N/A
- Average True Range (ATR)
- KODK 0.19
- KYTX 0.00
- MACD
- KODK -0.00
- KYTX 0.00
- Stochastic Oscillator
- KODK 11.13
- KYTX 0.00
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. The company operates via several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.